The patient had been diagnosed with mild-to-moderate ulcerative colitis (UC) a month prior to presentation for which she was prescribed oral mesalamine.
Your search for tofacitinib returned 25 results
The following article is a part of conference coverage from the 2019 Advances in Inflammatory Bowel Diseases (AIBD) Meeting, being held in Orlando, Florida. The team at MPR will be reporting on the latest news and research conducted by leading experts gastroenterology. Check back for more from the 2019 AIBD Meeting. Combination biologic therapy may…
According to new research over 1 in 5 patients with inflammatory bowel disease (IBD) should have started treatment with an advanced systemic therapy earlier in their disease.
In patients with ulcerative colitis (UC), tofacitinib, a Janus kinase inhibitor, was associated with improved short-term efficacy, when compared with vedolizumab, an integrin receptor antagonist. Findings were presented at the Advances in Inflammatory Bowel Disease (AIBD) 2019 meeting in Orlando, Florida.
A recently published report presented at the 2019 AIBD Annual Meeting in Orlando, FL, discussed the case of a patient who developed ulcerative colitis (UC) following treatment with Secukinumab for her psoriatic arthritis and highlighted a novel approach for the management of both of her conditions simultaneously.
Treatment with tofacitinib appears to have little impact on extraintestinal manifestations (EIMs) in patients with moderate to severe ulcerative colitis (UC) and might even improve them, according to an analysis of the OCTAVE program. Findings were presented at the 2019 AIBD Annual Meeting in Orlando, Florida.
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
A reduction in risk for cardiovascular disease has been reported among patients with rheumatoid arthritis who are receiving concomitant therapy with methotrexate and biologic disease-modifying antirheumatic drugs.
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
The researchers concluded their findings indicate that for patients with RA, abatacept reduced the risk for diabetes and “potentially improved insulin sensitivity and glycemic profile.”